ill in Biological Technology
Navigation Links
ill in Biological Technology
Bacteria pack their own demise
...ans have several tens of thousands of genes. Toxin and antitoxin If your genetic information becomes damaged, you have a good chance of becoming ill or even dying. This is also true for bacteria, which over time developed a handy way of providing extra protection to important genes the toxin-anti...IKARIA(R) to In-License BioLineRx's BL-1040
...BL-1040 reinforces our commitment to deliver novel treatments to critically ill patients around the world," commented Daniel Tasse, President and CEO of Ik...re products and therapies address the significant unmet needs of critically ill patients. The company's lead product, INOmax(R) (nitric oxide) for inhalati...Berlin Heart Inc. Receives FDA Orphan Product Development Grant
... patients." About EXCOR(R) Pediatric The EXCOR Pediatric Ventricular Assist Device is a mechanical cardiac support system for critically ill pediatric patients suffering from severe heart failure. EXCOR Pediatric has been used in more than 500 pediatric patients worldwide ranging from newbo...Cumberland Pharmaceuticals Announces FDA Approval of Caldolor(TM)
...ificantly reducing their morphine use. Clinical trials including critically ill and non-critically ill patients with fever showed a significant reduction in temperature as compar......ious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. In September 2008, Medivation announced a global agreement with Pfizer Inc to develop and commercialize dimebon for the...
500th Patient Receives Berlin Heart EXCOR Pediatric Ventricular Assist Device
... available. About EXCOR(R) Pediatric The EXCOR Pediatric Ventricular Assist Device is a mechanical cardiac support system for critically ill pediatric patients suffering from severe heart failure. EXCOR Pediatric has been used in more than 500 pediatric patients worldwide ranging from newbo......cal Director, will be receiving donated units. The Medports are the medical offices located inside the airports responsible for care and evaluation of ill or injured travelers and employees. "Given the recent circumstances with the new type of H1N1 flu, we decided to increase the speed of our North ...
...t AACN's National Teaching Institute (NTI) and Critical Care Exposition, the world's largest conference for nurses who care for acutely and critically ill patients, May 16-21, in New Orleans, LA. The Central Line Management Program is the latest offering in a full menu of MSC simulation-based curriculum ...
Medivation Announces First Quarter 2009 Financial Results Teleconference and Webcast on May 11, 2009
...ious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. In September 2008, Medivation announced a global agreement with Pfizer Inc to develop and commercialize Dimebon for the...Medivation Announces Upcoming Scientific Presentations at Medical Conferences
...ous diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. In September 2008, Medivation announced a global agreement with Pfizer Inc to develop and commercialize Dimebon for th......sed assay systems. While the former technology is restricted by the optical pathways already established by its microscope based design, the latter is ill suited for crucial add-ons to support microfluidic devices intended for the biological community. Nanopoint's CT-2000 helps in overcoming such limitat...
Medivation Reports Fourth Quarter and Year-End 2008 Financial Results and Provides Corporate Update
...ious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. In September 2008, Medivation announced a global agreement with Pfizer Inc to develop and commercialize Dimebon for the......ous diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. In September 2008, Medivation announced a global agreement with Pfizer Inc to develop and commercialize Dimebon for th...
...as, Virginia and Wisconsin). A wholly-owned subsidiary of Chemed Corporation (NYSE: CHE ), VITAS employs 9,079 professionals who care for terminally ill patients daily, primarily in the patients' homes, but also in the company's 25 inpatient hospice units as well as in hospitals, nursing homes and assi...
...erted form of Coenzyme Q10 positively impacted heart function in critically ill subjects HOUSTON, Feb. 18 /PRNewswire/ -- Results from the first clini...f Coenzyme Q10 (CoQ10) dramatically boosted ejection fraction in critically ill patients. Published in the January 2009 issue of Biofactors , a peer-revi...
Cordex Pharma Forms Heart Failure Medical Advisory Board
...e. Eventually, we hope to make the drug available to treat the desperately ill heart failure patients worldwide." About Heart Failure Heart fail...y and efficacy of CDP-1050, the availability of CDP-1050 worldwide to treat ill heart failure patients, ATPace's expected entry into a pivotal Phase 3 clin...Sirius Genomics Announces New Collaboration with UK Critical Care Genomics Group
...ted Kingdom representing more than 35 hospitals. The group's primary objective is to undertake clinical functional genomics research in the critically ill and to develop related collaborative, laboratory based research projects with scientific colleagues. About Sirius Genomics: www.siriusgenomics.c...Azur Pharma Announces the Licensing of Niravam, Parcopa, Kemstro and Fluxid From UCB
...emstro are central nervous system ("CNS") products. Azur Pharma's CNS business currently markets FazaClo(R) in the U.S. for the management of severely ill schizophrenic patients who fail to respond adequately to standard schizophrenia drug treatments. FazaClo is supplied as an innovative orally disintegr...Ikaria(R) to Present at 27th Annual JPMorgan Healthcare Conference
...utics company focused on the development and commercialization of innovative pharmaceuticals and drug-device combinations for hospitalized, critically ill patients. The company's lead product, INOmax(R) (nitric oxide) for inhalation, is the only FDA-approved drug for the treatment of hypoxic respiratory ...Chimerix Completes Phase I Study and Initiates a Phase II Multi-dose Clinical Trial for CMX001
...cause significant human morbidity and mortality. A safe, orally active antiviral drug to treat smallpox infection is needed to help people who become ill after exposure to the disease or those who cannot be vaccinated. The work is partially funded by a $36.1 million grant awarded to the company by the ...Purdue researcher invents molecule that stops SARS
...spiratory Syndrome, spread through two dozen countries over a period of a few months before it was contained. A total of 8,098 people worldwide became ill and 774 died. In addition to its ability to block the SARS virus, the molecular compound that inhibits the virus provides new insights into a group...St. Joseph's Hospital and Medical Center to Utilize Clinical InfoNET System for Physicians
... has been a symbol of quality healthcare in the Phoenix Valley for 113 years. The hospital offers a wide range of services to treat the most severely ill and injured in the community. St. Joseph's is home to Barrow Neurological Institute, which is annually recognized as one of the top 10 neuroscience c...Medivation Presents New Data on Dimebon's Novel Mechanism of Action
...ious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. In September 2008, Medivation entered into a global agreement with Pfizer Inc to develop and commercialize Dimebon for ...Medivation Announces Participation in RBC Capital Markets 2008 Healthcare Conference
...ious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. In September 2008, Medivation entered into a global agreement with Pfizer Inc to develop and commercialize Dimebon for ...Kiadis Pharma Announces Continued Collaboration With Professor Velardi on its Lead Product ATIR(TM)
...mpany with three products in different phases of clinical development. The company develops products that offer novel treatment options for terminally ill cancer patients and address significant unmet medical needs. The key focus indication for Kiadis Pharma is limitations and complications of bone marro...MultiVu Video Feed: New Rapid Test to Diagnose Flu May Help With Upcoming Flu Season
... 3M(TM) Rapid Detection Flu A+B Test Differentiates Flu Strains A & B In 15 Minutes Each year up to 20 percent of the U.S. population becomes ill with "the flu." Misdiagnosis of the flu is common as some bacterial infections present similarly to influenza. Because of this, overuse and unnecessar...USDA Awards $1.5 Million to Expand Access to High-Quality Critical Care in Rural Communities
...tise and a greater sense of security to critically ill patients and their families. Last month, Alegent...n only equipped to stabilize trauma and critically ill patients before transferring them to the nearest f... treatment and management of trauma and critically ill patients. "It's like OnStar for nurses," said eF...Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update
...ious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. The Company's current clinical development program includes a pivotal and confirmatory Phase 3 trial of Dimebon in Alzh...Medivation Announces Third Quarter 2008 Teleconference and Webcast on November 10, 2008
...ious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. The Company's current clinical development program includes a pivotal and confirmatory Phase 3 trial of Dimebon in Alzh...... a range of dose levels. Portola may develop betrixaban for additional indications including prevention of venous thromboembolism (VTE) in medically ill patients and in those undergoing major orthopedic surgery, treatment and secondary prevention of VTE, and acute coronary syndromes (ACS). About Atri...
...taining an accurate and rapid result for MRSA is absolutely key at the emergency admission point in hospitals. For example, if a patient is critically ill and needs to be admitted to the ICU without delay, clinicians simply cannot afford to wait two to three days for a culture result to see whether the p...
Vaxart Demonstrates Efficacy of Oral Avian Flu Vaccine in Preclinical Studies
...ed the challenge and were healthy as demonstrated by weight gain after challenge, while all 12 control ferrets either died (67 percent) or became very ill (33 percent). These results, if confirmed in human immunogenicity studies, compare well to the approved, injectable avian flu vaccine that achieved pr...Leading Heart Specialist Joins Duska Therapeutics as Scientific Consultant
...clinical trial, Duska's CDP-1050 is expected to commence a Phase 2 clinical trial, the laboratory research will be translated into a new treatment for ill heart failure patients and that the involvement of Dr. Stamler with Duska will provide us with tremendous strategic advantages. The forward-looking st...Medivation Announces Expiration of Hart-Scott-Rodino Waiting Period for Collaboration With Pfizer
...ious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. The Company's current clinical development program includes a pivotal and confirmatory Phase 3 trial of Dimebon in Alzh......ious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. The Company's current clinical development program includes a pivotal and confirmatory Phase 3 trial of Dimebon in Alzh...
Medivation Receives Corporate Achievement Award From Huntington's Disease Society of America
...ious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. The Company's current clinical development program includes a pivotal and confirmatory Phase 3 trial of Dimebon in Alzh...Ikaria Strengthens Executive Leadership Team
... on the development and commercialization of innovative pharmaceuticals, biologic messengers and drug-device combinations for hospitalized, critically ill patients. The company's lead product, INOmax(R) (nitric oxide) for inhalation, is the only FDA-approved drug for the treatment of hypoxic respiratory ...Global Psychiatrists Unite to Improve Services in Mental Health
...psychiatric care services and a lack of consensus as to which health care professional should be responsible for the prevention management of physical ill health. Sigrid Steffen, President of the European Federation of Associations of Families of People with Mental Illness (EUFAMI) said: "For the past ......ious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. The Company's current clinical development program includes a pivotal and confirmatory Phase 3 trial of Dimebon in Alzh...
...ilability of accurate and rapid scanning of trauma patients makes its placement in the emergency department ideal for managing the needs of critically ill patients without having to move them from floor to floor for radiological imaging. "With the speed, the small footprint of its design and the adapti...
Other TagsWedgeTriggerTriggerECTRAECTRA
MainstayWedgeBioZipRCBArthroRivetAnchorSewUmbrellaSuturelessCollaredCollarlessTriggerOgdenECTRAAZTEC
Breaking Biology News(10 mins):Climate projections underestimate CO2 impact 2University of Washington professor garners Avanti Young Investigator Award 2New engineering institute to modify, develop technology for the global poor 2New engineering institute to modify, develop technology for the global poor 3AUDIO from Medialink and Forest Laboratories 3A Dangers of Switching Medications 54578 1Senetek PLC Reports Second Quarter 2009 Financial Results 54573 1Senetek PLC Reports Second Quarter 2009 Financial Results 54573 2Senetek PLC Reports Second Quarter 2009 Financial Results 54573 3Senetek PLC Reports Second Quarter 2009 Financial Results 54573 4Senetek PLC Reports Second Quarter 2009 Financial Results 54573 5Senetek PLC Reports Second Quarter 2009 Financial Results 54573 6Rich Poor See Similar Declines in Old Age 54568 1Rich Poor See Similar Declines in Old Age 54568 2
Breaking Medicine News(10 mins):Health News:Bone Drugs May Beat Back Breast Cancer 2Health News:Major New Study Finds Soyfoods Safe and Beneficial for Women With Breast Cancer 2Health News:NBTY to be Featured on the FOX Business Program FOXBusiness.com LIVE 2Health News:Abington Health Announces New President and CEO 2Health News:Abington Health Announces New President and CEO 3Health News:American Association of Poison Control Centers: Treat Poinsettias and Mistletoe with Respect Rather Than Fear This Holiday Season 2
Other Contentsscreeningscreeningscreeningscreeningscreeningscreeningscreeningscreeningscreeningscrotumscrotumpagepagepagepagepagepagepagepagepageoocyteoocyteoocyteoocyteoocytepalatepalatepalatesecretincoatcoatcoatcoatcoatcoatcoatcoat[0] Bone Drugs May Beat Back Breast Cancer[0] Major New Study Finds Soyfoods Safe and Beneficial for Women With Breast Cancer[0] NBTY to be Featured on the FOX Business Program FOXBusiness.com LIVE[0] Abington Health Announces New President and CEO [0] American Association of Poison Control Centers: Treat Poinsettias and Mistletoe with Respect Rather Than Fear This Holiday Season
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |